3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Urologic Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Hemorrhage
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Advanced Ovarian Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
avelumab
7
Nivolumab
5
pembrolizumab
4
Specimen Handling
3
Ipilimumab
3
Biopsy
3
cemiplimab
2
atezolizumab
2
Radiotherapy
2
Magnetic Resonance Spectroscopy
2
tocilizumab
1
talimogene laherparepvec
1
prednylidene
1
poly ICLC
1
lutetium Lu 177 dotatate
1
lenvatinib
1
fludarabine phosphate
1
fludarabine
1
flt3 ligand protein
1
durvalumab
1
deltacortene
1
Tacrolimus
1
Saline Solution
1
Radiosurgery
1
Radiation
1
Prednisone
1
MAPRE1 protein, human
1
Lutetium-177
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Carcinoma, Merkel Cell
×
Saline Solution
×
Clear all
NCT03271372
2026-05-12
ADAM
University of Washington
Phase 3
Active not recruiting
101 enrolled